New data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting®, taking place November 1-5 in…
Source:Data from Boehringer Ingelheim’s HCV clinical program accepted for presentation at The Liver Meeting
Tuesday, October 1, 2013
Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment